Lucid DiagnosticsLUCD
LUCD
About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Employees: 70
0
Funds holding %
of 6,815 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more capital invested
Capital invested by funds: $1.74M [Q2] → $2M (+$259K) [Q3]
0.5% more ownership
Funds ownership: 4.05% [Q2] → 4.54% (+0.5%) [Q3]
18% less funds holding
Funds holding: 34 [Q2] → 28 (-6) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
142%
upside
Avg. target
$3.63
339%
upside
High target
$7
748%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 46% 1-year accuracy 31 / 68 met price target | 748%upside $7 | Buy Maintained | 9 Dec 2024 |
Cantor Fitzgerald Ross Osborn 52% 1-year accuracy 26 / 50 met price target | 142%upside $2 | Overweight Maintained | 15 Nov 2024 |
Canaccord Genuity Kyle Mikson 54% 1-year accuracy 15 / 28 met price target | 263%upside $3 | Buy Maintained | 14 Nov 2024 |
Needham Mike Matson 49% 1-year accuracy 59 / 121 met price target | 203%upside $2.50 | Buy Reiterated | 14 Nov 2024 |
Financial journalist opinion
Based on 4 articles about LUCD published over the past 30 days
Neutral
PRNewsWire
1 day ago
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW YORK , Jan. 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced it performed a record number of commercial EsoGuard® Esophageal DNA Tests during the fourth quarter of 2024. The preliminary total of 4,042 tests, the highest quarterly test volume in the Company's history, represents a sequential increase of 45 percent from the third quarter 2024 and an annual increase of 84 percent from the fourth quarter of 2023, demonstrating continued growing demand for EsoGuard esophageal precancer testing.
Positive
Zacks Investment Research
2 weeks ago
Lucid Inks New Partnership With VITALExam: Stock to Gain?
LUCD collaborates with VITALExam to enhance access to the EsoGuard Esophageal DNA Test. The partnership launches a fully contracted testing event for Tuscaloosa firefighters.
Neutral
PRNewsWire
3 weeks ago
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it had received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company was eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company now has until June 16, 2025 to meet the requirement.
Neutral
PRNewsWire
3 weeks ago
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters
Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC (VITALExam), a comprehensive medical care provider for first responders founded by Chief Executive Officer Marci Vitale, DNP, FNP-BC, AGACNP-BC, to enhance access to Lucid's EsoGuard® Esophageal DNA Test for firefighters at risk for esophageal precancer. Lucid and VITALExam launched the partnership with a fully-contracted #CheckYourFoodTube Precancer Testing Event at Tuscaloosa Fire Rescue in Tuscaloosa, AL, as part of Lucid's expanded direct contracting initiative focused on driving near-term EsoGuard revenue.
Neutral
PRNewsWire
1 month ago
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW YORK , Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its CLinical Utility of EsoGuard (CLUE) study has been accepted for publication in the peer-reviewed journal Medicina . This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard® Esophageal DNA Test.
Neutral
PRNewsWire
1 month ago
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones
New convertible debt financing with existing long-term equity shareholders yields ~$18M in net cash proceeds after paying off existing convertible debt NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a convertible debt refinancing transaction that strengthens its balance sheet and extends its cash runway past near-term reimbursement milestones. Lucid issued five-year convertible notes to long-term equity shareholders in an aggregate principal amount of $21.95 million.
Neutral
PRNewsWire
1 month ago
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has submitted its complete clinical evidence package for its EsoGuard® Esophageal DNA Test in support of a Request for Reconsideration of Local Coverage Determination (LCD) L39256 "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, and Neoplasia" to Molecular Diagnostics Program (MolDX), administered by Palmetto GBA, a Medicare Administrative Contractor (MAC) for the Centers for Medicare & Medicaid Services (CMS), to seek coverage for EsoGuard. "This submission is the culmination of many years of persistent hard work by our team and our many clinical research partners, and represents perhaps the most important milestone in Lucid's history," said Lishan Aklog, M.D.
Neutral
PRNewsWire
1 month ago
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024 at 1:30 p.m. ET. Live and replay webcasts may be accessed on the investor relations section of the Company's website at ir.luciddx.com.
Neutral
Seeking Alpha
2 months ago
Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Matt Riley - Director-Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Mark Massaro - BTIG Anthony Vendetti - Maxim Group Mike Matson - Needham Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2024 Business Update Conference Call. At this time, all lines are in a listen-only mode.
Neutral
PRNewsWire
2 months ago
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13 th at 8:30 AM EST NEW YORK , Nov. 13, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024. Conference Call and Webcast The webcast will take place on Wednesday, November 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Charts implemented using Lightweight Charts™